Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan, Thibault Mazard, Carlos Gomez‐Roca, Jean‐Philippe Metges, Carine Bellera, Antoine Adenis, Iphigénie Korakis, Pierre-Guillaume Poureau, Kévin Bourcier, Maud Toulmonde, Michèle Kind, Christophe Rey, Céline Auzanneau, Alban Bessede, Isabelle Soubeyran, Antoîne Italiano
Topics & Concepts
MedicineRegorafenibRashInternal medicineClinical endpointProgressive diseaseHazard ratioGastroenterologyAdverse effectAvelumabProgression-free survivalPhases of clinical researchOncologySurgeryClinical trialCancerColorectal cancerConfidence intervalChemotherapyImmunotherapyNivolumabCholangiocarcinoma and Gallbladder Cancer StudiesMetastasis and carcinoma case studiesInflammasome and immune disorders